Inflammatory and circulatory effects of the reduction of endotoxin concentration in established porcine endotoxemic shock—A model of endotoxin elimination

Objective:To study whether a reduction of the endotoxin load, once a generalized inflammatory state has been established, reduces the inflammatory response and endotoxin-induced effects on circulation, hypoperfusion, and organ dysfunction. Design:Prospective parallel-grouped placebo-controlled randomized interventional experimental study. Setting:University research unit. Subjects:Healthy pigs. Interventions:The animals were subjected to a continuous endotoxin infusion rate of either 4.0 or 0.063 μg endotoxin × kg−1 × h−1 for 1, 2, or 6 hours. The 1- and 2-hour infusion groups represented the applied therapy by a reduction of the endotoxin load of 5/6 and 2/3, respectively. Measurements and Main Results:During a 6-hour experiment, laboratory and physiologic parameters were recorded hourly in 26 anesthetized and mechanically ventilated pigs. Primary end point was to detect differences in tumor necrosis factor-α (TNF-α) concentration during the last 3 hours of the experiment. Despite the early reduction of the endotoxin load, no effect on TNF-α concentration was observed. Similarly, in circulatory parameters, such as mean arterial pressure and oxygen delivery, and in platelet count and renal function, no effects were noted. However, there was some improvement in pulmonary compliance and function as determined by Pao2, Paco2, and pH. These changes were associated with slight improvements in leukocyte response and capillary leakage. Conclusions:Termination of the endotoxin infusion represents an incontestable model of endotoxin concentration reduction. Endotoxin elimination strategies applied at the TNF-α peak or later will have very little or no effect on TNF-α–mediated toxicity. Nevertheless, there was an effect on the leukocyte response that was associated with an improvement in respiratory function and microcirculation, making it impossible to rule out fully the beneficial effect of this strategy. However, the effects were limited in relation to the magnitude of the endotoxin concentration reduction and the very early application of the antiendotoxin measure.

[1]  A. Larsson,et al.  EFFECT OF THE ADMINISTRATION RATE ON THE BIOLOGICAL RESPONSES TO A FIXED DOSE OF ENDOTOXIN IN THE ANESTHETIZED PIG , 2007, Shock.

[2]  A. Larsson,et al.  Inflammatory, coagulatory and circulatory responses to logarithmic increases in the endotoxin dose in the anaesthetised pig , 2006, Journal of endotoxin research.

[3]  D. Inthorn,et al.  EXTRACORPOREAL PLASMA TREATMENT FOR THE REMOVAL OF ENDOTOXIN IN PATIENTS WITH SEPSIS: CLINICAL RESULTS OF A PILOT STUDY , 2005, Shock.

[4]  J. Vincent,et al.  A PILOT-CONTROLLED STUDY OF A POLYMYXIN B-IMMOBILIZED HEMOPERFUSION CARTRIDGE IN PATIENTS WITH SEVERE SEPSIS SECONDARY TO INTRA-ABDOMINAL INFECTION , 2005, Shock.

[5]  R. Balogun,et al.  Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected gram-negative sepsis. , 2005, Critical care medicine.

[6]  E. Neugebauer,et al.  Extracorporeal endotoxin adsorption in septic patients--does it work? , 2004, Critical care medicine.

[7]  J. Marshall,et al.  Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence , 2002, Critical care.

[8]  Y. Kanno,et al.  Newly Developed Immobilized Polymyxin B Fibers Improve the Survival of Patients with Sepsis , 2001, Blood Purification.

[9]  E. Rietschel,et al.  Bacterial lipopolysaccharides and innate immunity. , 2001, Journal of endotoxin research.

[10]  S. Dower,et al.  A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/MD2. , 2001, The Journal of infectious diseases.

[11]  J. A. Kruse,et al.  E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.

[12]  S. Opal,et al.  Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. , 1999, The Journal of infectious diseases.

[13]  T. van der Poll,et al.  Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. , 1996, The Journal of clinical investigation.

[14]  Craig R. Smith,et al.  Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial , 1995 .

[15]  T. Tani,et al.  Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. , 1994, American journal of surgery.

[16]  J. Vincent,et al.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.

[17]  Jerome J. Schentag,et al.  A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis , 1991 .

[18]  M. A. Martin,et al.  A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. , 1991, JAMA.

[19]  J. Schellekens,et al.  Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon-α, and Interferon-γ in the Serum of Patients with Septic Shock , 1990 .

[20]  J. Schellekens,et al.  Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. , 1990, The Journal of infectious diseases.

[21]  P. Brandtzaeg,et al.  Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. , 1989, The Journal of infectious diseases.

[22]  J. McCutchan,et al.  TREATMENT OF GRAM-NEGATIVE BACTEREMIA AND SHOCK WITH HUMAN ANTISERUM TO A MUTANT ESCHERICHIA COLI , 1983 .